183 related articles for article (PubMed ID: 28358432)
1. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
[TBL] [Abstract][Full Text] [Related]
2. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
3. Cancer therapy with iRGD as a tumor-penetrating peptide.
Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
6. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
8. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
9. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
10. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
Zuo H
J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
[TBL] [Abstract][Full Text] [Related]
11. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
[TBL] [Abstract][Full Text] [Related]
12. iRGD peptide as effective transporter of CuInZnxS2+x quantum dots into human cancer cells.
Przysiecka Ł; Michalska M; Nowaczyk G; Peplińska B; Jesionowski T; Schneider R; Jurga S
Colloids Surf B Biointerfaces; 2016 Oct; 146():9-18. PubMed ID: 27244046
[TBL] [Abstract][Full Text] [Related]
13. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
14. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
[TBL] [Abstract][Full Text] [Related]
15. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
[TBL] [Abstract][Full Text] [Related]
16. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
17. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
18. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
[TBL] [Abstract][Full Text] [Related]
19. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
Zhang ZQ; Zhong CL; Zhao X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.
Hamilton AM; Aidoudi-Ahmed S; Sharma S; Kotamraju VR; Foster PJ; Sugahara KN; Ruoslahti E; Rutt BK
J Mol Med (Berl); 2015 Sep; 93(9):991-1001. PubMed ID: 25869026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
